Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDP1815 and EDP2939 Immunopharmacology in Healthy Volunteers
NCT05682222Phase 1Completed
- Sponsor
- Evelo Biosciences
- Start
- Jun 2022
- Primary completion
- Oct 2022
- Modality
- Microbiome Therapeutics, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of EDP1815 and EDP2939 in psoriasis (5 arms), sponsored by Evelo Biosciences. Primary endpoint: KLH-induced immune reaction. Started Jun 2022; status: completed.
02
Drugs
EDP1815EDP2939
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT05682222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05682222.